https://www.selleckchem.com/Androgen-Receptor.html
This study was undertaken to examine long-term (up to 7.8years) retention rate, safety, and tolerability of the antiseizure medication (ASM) cenobamate as adjunctive treatment in the open-label extension (OLE) of study YKP3089C013 (C013; ClinicalTrials.gov NCT01397968). Patients who completed the 12-week, multicenter, multinational, double-blind, randomized, placebo-controlled C013study, which examined adjunctive cenobamate treatment of adults with uncontrolled focal seizures, were eligible to enroll in the OLE. During the OLE, dose ad
Like
Comment
Share
